Adalimumab biosimilar (IBI303)
Autoimmune diseases
ApprovedCommercial
Key Facts
About Innovent Biologics
Innovent Biologics is one of China's premier biotechnology companies, established in 2011 and publicly traded on the Hong Kong Stock Exchange. The company specializes in developing innovative biologics for oncology, autoimmune, and metabolic diseases, with a strong focus on monoclonal antibodies and bispecific antibodies. Innovent has successfully commercialized multiple products in China and has strategic partnerships with global pharmaceutical companies including Eli Lilly and Roche.
View full company profileTherapeutic Areas
Other Autoimmune diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Inflammation & Immunology Programs | Pfizer | Phase 2/3 |
| ARGX-118 | Argenx | Phase 1 |
| Hulio (Adalimumab) | Biocon | Approved |
| Undisclosed ImmTAAI candidates | Immunocore | Preclinical |
| BHV-1100 (IgG degrader) | Biohaven | Preclinical |
| Bispecifics | Shattuck Labs | IND-Enabling |
| Preclinical Pipeline | Autolus Therapeutics | Pre-clinical |
| FT839 | Fate Therapeutics | Phase 1 |
| IMP761 | Immutep | Phase 1 (planned) |